111, INC. Transcending the Boundaries of Healthcare
NASDAQ: YI
Second Quarter 2021 Earnings Call
August 27, 2021
DISCLAIMER
The following presentation has been prepared by 111,. Inc. ("111" or the "Company") solely for informational purposes and should not be construed to be, directly or indirectly, in whole or in part, an offer to buy or sell and/or an invitation and/or a recommendation and/or a solicitation of an offer to buy or sell any security or instrument or to participate in any investment or trading strategy, nor shall any part of it form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities or otherwise.
This presentation does not contain all relevant information relating to the Company or its securities, particularly with respect to
the risks and special considerations involved with an investment in the securities of the Company. Nothing contained in this document shall be relied upon as a promise or representation as to the past or future performance of the Company. Past performance does not guarantee or predict future performance.
You acknowledge that any assessment of the Company that may be made by you will be independent of this document and that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.
This document contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target," "confident" and similar statements. Among other things, the Business Outlook and quotations from management in this announcement, as well as 111's strategic and operational plans, contain forward-looking statements. 111 may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Such statements are based upon management's current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control. Forward-looking
statements involve inherent risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. Potential risks and uncertainties include, but are not limited to, uncertainties as to the Company's ability comply with extensive and evolving regulatory requirements, its ability to compete effectively in the evolving PRC general health and wellness market, its ability to manage the growth of its business and expansion plans, its ability to achieve or maintain profitability in the future, its ability to control the risks associated with its pharmaceutical retail and wholesale businesses, and the Company's ability to meet the standards necessary to maintain listing of its ADSs on the Nasdaq Global Market,
including its ability to cure any non-compliance with Nasdaq's continued listing criteria. Further information regarding these and
other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and 111 does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
This document also contains non-GAAP financial measures, the presentation of which is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with accounting principles generally accepted in the United States of America. In addition, the Company's calculation of these non-GAAP financial measures may be different from the calculation used by other companies, and therefore comparability may be limited. The reconciliation of those measures to the most comparable GAAP measures is contained within this document or the earnings press release.
This document speaks as of June, 2021. Neither the delivery of this document nor any further discussions of the Company with any of the recipients shall, under and circumstances, create any implication that there has been no change in the affairs of the Company since that date.
111 Snapshot
Our Mission
Digitally Connecting Patients with Medicine and Healthcare Services
Our S2B2C Model
C
Patients
Serve
B
Pharmacies | Doctors |
Enable
S
Supply Chain Platform
S2B2C: "Supply Chain Platform to enable Businesses to better serve Consumers"
3
Continued Rapid Growth Since IPO
YoY | +100% | +102% | +99% | +109% | +123% | +142% | +140% | +94% | +113% | +96% | +65% | +87% | ||||
Net Revenue （Million ) | RMB 3,024 | |||||||||||||||
USD 468 | ||||||||||||||||
RMB 2,363 | RMB 2,643 | RMB 2,595 | ||||||||||||||
USD 405 | USD 396 | |||||||||||||||
RMB 1,576 | RMB 1,622 | USD 348 | ||||||||||||||
RMB 1,348 | USD 230 | |||||||||||||||
USD 223 | ||||||||||||||||
RMB 1,110 | USD 194 | |||||||||||||||
RMB 838 | ||||||||||||||||
RMB 656 | USD 155 | |||||||||||||||
RMB 498 | RMB 557 | USD 122 | ||||||||||||||
USD 98 | ||||||||||||||||
USD 72 | USD 81 | |||||||||||||||
2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 |
( Non-GAAP Net Loss as % of Net Revenue )
22.3%
19.7% | |||||||
14.7% | |||||||
10.1% | 9.9% | 10.7% | |||||
6.9% | |||||||
4.9% | 4.0% | 3.7% | 4.2% | 3.9% | |||
2018 Q3 | 2018 Q4 | 2019 Q1 | 2019 Q2 | 2019 Q3 | 2019 Q4 | 2020 Q1 | 2020 Q2 | 2020 Q3 | 2020 Q4 | 2021 Q1 | 2021 Q2 |
4
Delivering Strong Revenue and Gross Margin Growth
Revenue | Gross Margin | |
(Million) | (Million) |
YoY +87%
RMB 3,024
USD 468
RMB 1,621 | |
USD 230 | |
2020 Q2 | 2021 Q2 |
YoY +59%
RMB 135
USD 21
RMB 85 | |
USD 12 | |
2020 Q2 | 2021 Q2 |
5
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
111 Inc. published this content on 27 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 August 2021 06:40:10 UTC.
